Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Correction: Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA

  • The PLOS ONE Staff

Correction: Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA

  • The PLOS ONE Staff
PLOS
x

Notice of Republication

This article was republished on August 7, 2015, to replace Fig 2, which was incorrect. The publisher apologizes for the error. Please download this article again to view the correct version.

Reference

  1. 1. Ferreira A, Sagkriotis A, Olson M, Lu J, Makin C, Milnes F (2015) Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA. PLoS ONE 10(7): e0133968. pmid:26208030